Luca Arecco/X
Jun 1, 2025, 12:10
Luca Arecco: Sac-TMT Shows Promising Efficacy in Advanced TNBC as 1st-Line Therapy
Luca Arecco, Clinical Research Fellow at ESMO, posted on X:
“Rapid oral mBC
OptiTROP-Breast05: Sac-TMT shows 70% ORR and 13.4 mo PFS as 1st-line therapy in advanced TNBC (incl. pts with PD-L1–negative, CPS <10). Promising efficacy with no neuropathy or ILD. 2 phase III trials now underway in PD-L1–negative mTNBC.”
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post by Luca Arecco, adding:
“A first-line metastatic TNBC progression free survival beyond 1 year is very welcome for our patients and this was mostly PDL-1 negative.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 07:54
Jun 5, 2025, 05:59
Jun 5, 2025, 05:45
Jun 5, 2025, 05:05